Interim Report January - June 2007 Tripep AB (publ)

Interim Report January - June 2007 Tripep AB (publ)

• Research and development costs amounted to SEK 7.7 million
• The loss after tax was SEK 13.8 million
• Earnings per share were SEK 0.29
• The company had no net sales for the period
• The company has received patent protection for administration of ChronVac-C®
vaccine using electroporation

Events after the end of the reporting period
• After the end of the reporting period, Tripep received final approval to start
a clinical study of ChronVac-C® on patients with a chronic infection of the
Hepatitis C virus. The study is scheduled to start in September/October 2007.   



For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se


Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's Website: www.tripep.se .